<DOC>
	<DOCNO>NCT01968200</DOCNO>
	<brief_summary>Anthracycline base anti-tumoral therapy know develop cardiac damage could also lead heart failure . Monocentric study prove treatment ACE inhibitor ( ACEi ) betablockers ( BB ) first elevation cardiac troponin able reduce incidence heart failure ( HF ) . ICOS-ONE trial multicenter randomize trial compare two therapeutic strategy . The main objective ass whether enalapril start concomitantly AC-containing treatment , prevent cardiac toxicity effectively enalapril prescribe select patient show laboratory evidence injury chemotherapy , follow-up visit 268 patient .</brief_summary>
	<brief_title>Prevention Anthracycline-induced Cardiotoxicity</brief_title>
	<detailed_description>Anthracycline-containing chemotherapy well know cause dose-dependent , progressive cardiac damage particular leave ventricular dysfunction evolve heart failure . The development cardiac dysfunction , even asymptomatic , lead exclusion cancer patient effective chemotherapy , possible negative impact oncologic prognosis . The use troponins ( cTn ) cancer chemotherapy anthracyclines ( AC ) allow identify early cardiac injury onset leave ventricular dysfunction , high predictive value . ACE inhibitor ( ACEi ) betablockers ( BB ) prescribe cancer patient , course end chemotherapy , sign symptom cardiac failure detect , show protective monocentric study . Prophylaxis ACEi , enalapril BB , bisoprolol patient treat AC-chemotherapy may allow reduce risk cardiovascular injury , allow completion whole schedule antitumoral treatment . Sample size According previous study European Institute Oncology IEO ) , increase circulate troponin level estimate 20 % patient treat anthracyclines conventional dosage . 134 patient arm ( Total sample size 268 patient ) require detect 50 % relative risk reduction incidence elevate troponins level 2-sided alpha=0.05 1-beta=0.60 , take account 5 % drop-out rate . This endpoint allow compare strategy base prevention ( arm 1 ) strategy guide troponin ( arm 2 ) . Given originality proposal limited resource , study exploratory nature , wait large adequately powered clinical trial design observe significant difference clinical event . Safety Tolerability enalapril , valsartan bisoprolol proven several year broad population cardiac patient , heart failure , also cardiovascular risk absence sign symptom HF . Specific unwanted effect cancer patient expect , base previous experience . Special care take avoid profound hypotension induce enalapril , valsartan bisoprolol patient . Serious Adverse Events ( SAEs ) ad Suspected Unsuspected Serious Adverse Reactions ( SUSARs ) collect treat appropriately .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>1 . Patients diagnosis cancer indication first secondline therapy anthracyclines 2 . Age ≥18years 3 . Serum creatinine &lt; 177µmol/L ( 2mg/100mL ) 4 . Systolic blood pressure ≥100 mmHg ≤170 mmHg 5 . Left ventricular ejection fraction ( VEF ) &gt; 50 % 6 . Written informed consent . 7 . Life expectancy least 12 month 1 . Patients history clinical/instrumental evidence heart failure 2 . Patients history clinical/instrumental evidence ischemic heart disease ; 3 . Patients blood troponin level higher cutoff suggest manufacturer start cancer CT ; 4 . Systolic blood pressure &lt; 100 mmHg ; 5 . Heart rate &lt; 50 bpm ; 6 . Prior malignancy require potentially cardiotoxic chemotherapy ( e.g . anthracyclines , trastuzumab.. ) ; ; 7 . Uncontrolled hypertension define systolic blood pressure &gt; 170 mmHg ; 8 . Treatment ACEi , ARB BB within 4 week prior study start ; 9 . Known intolerance enalapril , except cough ; 10 . Planned treatment dexrazoxane ; 11 . Participation another experimental drug trial within 4 week prior study start ; 12 . Noncooperative behaviour suspect poor compliance ; 13 . Psychiatric disorder condition might impair ability give inform consent ; 14 . Pregnancy breast feeding ; 15 . Scheduled mediastinal radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>anthracyclines</keyword>
</DOC>